LivaNova PLC announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1, 2025. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. Blaise joins LivaNova after 19 years with ResMed in San Diego, a leader in the treatment of respiratory and sleep apnea conditions.
She held various leadership roles in marketing, sales, and strategy, including Senior Vice President of Strategy and Business Development, President of Sleep & Respiratory Care, and Vice President Western Europe (Benelux, France, Spain, Portugal, Italy, and North Africa). Prior to ResMed, Blaise served in multiple corporate management roles in France with companies including Löwenstein Medical, Thusane, and Medtronic. Blaise?s board service includes former director positions with the Medical Device Innovation Consortium in Washington, D.C., MedTech Europe Brussels, and the National Union of the Medical Technologies Industry in France, where she also served as chairperson.
Blaise holds a bachelor?s degree in International Business from the University of Sheffield in the U.K. and an MBA from Kedge Business School in Talence, France.
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Companyâs next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
